Last checked at 16 Apr 2019 07:00
SkinBioTherapeutics plc
Director Dealing
Manchester, UK - 16 April 2019 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company"), a life science company focused on skin health, announces it was notified on 15 April 2019, that Dr Cathy Prescott, a Non-Executive Director of the Company, acquired 56,112 ordinary shares on 15 April 2019 at a price of 17.82p per share.
Dr Prescott now holds 56,112 ordinary shares in the Company, representing 0.04% of the Company's issued share capital.
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
For more information please contact:
SkinBioTherapeutics plc Dr Cath O'Neill, CEO Doug Quinn, CFO
| Tel: +44 (0) 161 468 2760 |
Cairn Financial Advisers LLP (Nominated Adviser) Tony Rawlinson / Sandy Jamieson / Richard Nash
| Tel: +44 (0) 20 7213 0880 |
Turner Pope Investments (Joint Broker) Ben Turner / James Pope
SP Angel Corporate Finance (Joint Broker) Vadim Alexandre / Abigail Wayne
| Tel: +44 (0) 20 3621 4120
Tel: +44 (0) 20 3470 0470 |
Instinctif Partners Melanie Toyne-Sewell / Deborah Bell | Tel: +44 (0) 20 7457 2020 SkinBio@instinctif.com |
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr. Catherine O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).
The Company joined AIM in April 2017, concurrent with raising £4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Dr Cathy Prescott | |||||
2 | Reason for notification | Acquisition of shares | |||||
a. | Position/Status | Non-Executive Director | |||||
b. | Initial notification/ Amendment | Initial notification | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | SkinBioTherapeutics Plc | |||||
b. | LEI | 213800YMQOCB23FX6I06
| |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of 1p each
ISIN: GB00BF33H870
| |||||
b. | Nature of the transaction | Share purchase | |||||
c. | Price(s) and volume(s) |
|
|
|
|
| |
| Price(s) per share | Volume(s) |
| ||||
17.82p | 56,112 |
| |||||
| |||||||
d. | Aggregated information
- Aggregated Volume
- Price |
56,112
17.82p
| |||||
e. | Date of the transaction | 15th April 2019 | |||||
f. | Place of the transaction | London Stock Exchange | |||||